CytoDyn Form 8-K Summary (Nov 3, 2025)

CytoDyn entered a Standby Equity Purchase Agreement with Yorkville providing access to capital over 36 months.

Key Investor Metrics:

• Financing Type: Standby Equity Facility (ATM-like structure).
• Maximum Capital: Up to $30,000,000 aggregate commitment amount.
• Pricing: Shares sold at 98% of the lowest 3-day VWAP when drawn.
• Use of Proceeds: Expected for working capital and debt repayment.

Critical Details:

• The Company retains the right, but not the obligation, to sell shares.
• Issuances are c